首页> 外文期刊>Journal of Current Ophthalmology >Outcomes of vitrectomy, membranectomy and internal limiting membrane peeling in patients with refractory diabetic macular edema and non-tractional epiretinal membrane
【24h】

Outcomes of vitrectomy, membranectomy and internal limiting membrane peeling in patients with refractory diabetic macular edema and non-tractional epiretinal membrane

机译:难治性糖尿病性黄斑水肿和非牵拉性视网膜前膜的玻璃体切除术,膜切开术和内部限制膜剥离的结果

获取原文
           

摘要

Purpose To evaluate the efficacy of vitrectomy, membranectomy, and internal limiting membrane (ILM) peeling on macular thickness and best corrected visual acuity (BCVA) in patients with refractory diffuse diabetic macular edema (DME) and non-tractional epiretinal membrane (NT-ERM). Methods This prospective interventional case series included eyes with refractory DME (central subfield macular thickness [CSMT]??300?μm) after at least two intravitreal injections of bevacizumab (IVB) and one intravitreal injection of triamcinolone (IVT), and accompanying NT-ERM. Complete ophthalmic examination, baseline spectral domain optical coherence tomography (SD-OCT), and fluorescein angiography (FA) were performed prior to 23 gauge pars plana vitrectomy with membranectomy and internal limiting membrane (ILM) peeling. Postoperative evaluation was done with clinical examination and SD-OCT. Linear mix model analysis was used to study postoperative results. Results Twelve eyes from 11 patients (5 males) with a mean age of 60.33?±?9.01 (range 46–73 years) were included. The mean follow-up time was 13.5?±?4.48 months (range 4–20 months). A significant reduction in CSMT was found (from 559?±?89?μm to 354?±?76?μm; P?=?0.001), with a non-significant BCVA change (from 0.84?±?0.32 logMAR to 0.72?±?0.2 logMAR; P?=?0.967). There was no significant correlation between CSMT and BCVA (partial correlation?=??0.115, P?=?0.445) and also between estimated mean CSMT change per month and estimated mean BCVA change per month (r?=?0.337, P?=?0.283). Conclusion In this series, our results did not show that vitrectomy, membranectomy, and ILM peeling result in significant improvement of BCVA in eyes with refractory DME and non-tractional ERM in spite of central macular thickness reduction.
机译:目的评估玻璃体切除,膜切开术和内部限制膜(ILM)剥离对难治性弥漫性糖尿病性黄斑水肿(DME)和非牵引性视网膜前膜(NT-ERM)患者的黄斑厚度和最佳矫正视力(BCVA)的疗效)。方法该前瞻性干预病例系列包括至少两次玻璃体内注射贝伐单抗(IVB)和玻璃体内注射曲安奈德(IVT)后伴有难治性DME(中央亚视野黄斑厚度≥300μm)的眼睛。 -ERM。在进行23口标准平玻璃体切除术并进行膜切开术和内部限制膜(ILM)剥皮术之前,先进行完整的眼科检查,基线光谱域光学相干断层扫描(SD-OCT)和荧光素血管造影(FA)。术后评估通过临床检查和SD-OCT进行。线性混合模型分析用于研究术后结果。结果纳入11眼12眼(5例男性),平均年龄60.33±±9.01(范围46-73岁)。平均随访时间为13.5±4.48个月(4-20个月)。发现CSMT显着降低(从559?±?89?μm降至354?±?76?μm; P?=?0.001),BCVA变化不明显(从0.84?±?0.32 logMAR降至0.72?log)。 ±≤0.2 logMAR; P≤0.967)。 CSMT与BCVA之间无显着相关性(偏相关性= 0.115,P = 0.445),每月估算的平均CSMT变化与估算的平均BCVA变化也无显着相关性(r = 0.337,P = 0)。 0.283)。结论在该系列研究中,尽管中央黄斑厚度减少,但玻璃体切除术,膜切开术和ILM剥离并未使难治性DME和非牵引性ERM的眼睛的BCVA显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号